Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial Meeting Abstract
| Authors: | Curigliano, G.; O'Shaughnessy, J.; Bidard, F. C.; Kim, S. B.; Tokunaga, E.; Aftimos, P. G.; Manich, C. S.; Carey, L. A.; Okera, M.; Melo, É.; Zagouri, F.; Magallanes, M.; Karadurmus, N.; Bahadur, S. W.; Speck, R. M.; Wang, X. A.; Young, S. R. L.; Jhaveri, K. L.; Harbeck, N. |
| Abstract Title: | Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | 1001 |
| Language: | English |
| ACCESSION: | WOS:001509301300001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.1001 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
